Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation (Nasdaq: XOMA) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its royalty aggregation business, capital structure, and transaction activity. On this page, you can review XOMA Royalty’s SEC filings alongside AI-powered summaries that help explain the key points in accessible language.
For investors analyzing XOMA Royalty, Form 10-K annual reports and Form 10-Q quarterly reports provide detail on royalty and milestone receipts, portfolio composition, risk factors, and accounting for acquired economic interests. Form 8-K current reports document material events such as the completion of acquisitions of HilleVax, LAVA Therapeutics, and Mural Oncology, entry into at-the-market sales agreements for common and preferred stock, and announcements of financial results.
XOMA Royalty’s filings also describe its listed securities, including common stock (XOMA) and preferred instruments such as 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) and depositary shares representing 8.375% Series B Cumulative Perpetual Preferred Stock (XOMAO). Related registration statements and prospectus supplements outline how proceeds from these offerings may be used to acquire additional potential royalty and milestone revenue streams, fund preferred dividends, and support general corporate purposes.
In addition, Form 4 insider transaction reports and proxy materials can provide insight into equity ownership and governance, while exhibits to 8-K filings include key agreements such as merger agreements, share purchase agreements, contingent value rights agreements, and sales agreements. Stock Titan’s interface enhances these filings with AI-generated highlights that point out important terms, transaction structures, and potential implications for XOMA Royalty’s royalty and milestone portfolio, helping readers navigate complex legal and financial disclosures more efficiently.
XOMA Royalty Corp director Joseph M. Limber exercised stock options to acquire 3,026 shares of common stock at $11.20 per share. The options, which had been fully vested and exercisable since July 21, 2017, were fully exercised, leaving no remaining options from this grant. Following the exercise, he directly holds 9,234 shares of common stock, 20,000 depositary shares of 8.375% Series B cumulative stock, and 10,000 shares of 8.625% Series A cumulative perpetual preferred stock.
XOMA Royalty Corporation has called a virtual annual stockholder meeting for May 21, 2026, and is asking investors to vote on board elections, auditor ratification, equity plans and executive pay. Seven directors, including CEO Owen Hughes and independent chair Jack L. Wyszomierski, are nominated for one-year terms.
Stockholders are asked to ratify Deloitte & Touche as 2026 auditor, approve a 425,000-share increase to the 2010 Long Term Incentive and Stock Award Plan (about 2.5% dilution including 5,003,000 Series X convertible shares), adopt a new 2026 Employee Stock Purchase Plan for 500,000 shares, and give a non-binding say-on-pay vote on executive compensation.
XOMA Royalty Corp amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led to disaggregated reporting by Vanguard subsidiaries.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing lists Vanguard's Malvern address and XOMA's principal office at 2200 Powell St, Emeryville, CA.
XOMA Royalty Corp director Jack L. Wyszomierski exercised stock options and increased his direct common share holdings. On March 24, 2026, he exercised a Stock Option for 3,026 shares at $11.20 per share, receiving the same number of Common Stock shares. Following the transaction, he directly owns 21,530 shares of XOMA Royalty Corp common stock. The option had been fully vested and exercisable since July 21, 2017, indicating a routine derivative exercise rather than an open-market purchase or sale.
XOMA Royalty Corporation reports on its 2025 performance as a diversified biotech royalty aggregator. The company now holds economic interests in over 120 assets, including seven commercial products and 14 late-stage programs, and focuses on non-dilutive funding of drug developers.
In 2025, XOMA received $33.6 million in commercial payments and $16.9 million from milestones and other fees, for total cash receipts of $50.5 million. Key commercial contributors included VABYSMO, OJEMDA, MIPLYFFA and IXINITY. DSUVIA revenue was minimal after Alora discontinued commercial sales and later withdrew the product due to manufacturing constraints.
The company expanded its portfolio through transactions such as the Takeda Revenue Share Agreement, Castle Creek’s D‑Fi royalty financing, and acquisitions of Pulmokine and LAVA, adding rights to multiple late‑stage and partnered programs. It also executed a stock repurchase program, buying 648,708 shares for $16.1 million by year-end, and operated with a lean team of 14 employees.
XOMA Royalty Corporation reported a strong turnaround for 2025, with income and revenues rising to $52.1 million from $28.5 million in 2024 and net income improving to $31.7 million from a net loss of $13.8 million.
Cash receipts reached $50.5 million, including $33.6 million in royalties and commercial payments and $16.9 million in milestones and fees, and the company generated positive cash flow from operations. XOMA deployed $25.0 million to acquire additional royalty and milestone assets and repurchased 648,048 common shares for $16.0 million.
At December 31, 2025, XOMA held cash and cash equivalents of $133.7 million, including $50.8 million in restricted cash, against long-term debt of $96.5 million. The portfolio expanded to more than 100 assets, with multiple commercial and late-stage programs supporting growing royalty streams.
Hughes Owen reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director and Chief Executive Officer Owen Hughes reported new equity awards. On March 16, 2026, he received 126,813 Performance Stock Units, each representing a contingent right to one share of common stock, which vest only if the stock reaches specified price targets and he remains in service.
He was also granted 82,428 restricted stock units payable solely in common stock. These RSUs vest in four equal 25% installments on each of the first four anniversaries of March 11, 2026, subject to continued service. Following these awards, he holds 180,696 common shares directly, 295 common shares indirectly via a 401(k) plan, and 102,000 depositary shares of 8.375% Series B cumulative stock.
Sitko Bradley reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp’s Chief Investment Officer Bradley Sitko reported equity awards rather than market trades. He received 44,849 Performance Stock Units, each representing the right to one share of common stock if specified share-price goals are met and he remains with the company through the vesting dates.
He was also granted two blocks of common-stock RSUs at no cash cost: 30,000 shares and 29,402 shares. One RSU grant vests fully on March 11, 2031, and the other vests 25% on each of the first four anniversaries of March 11, 2026, all conditioned on continued service.
Following these grants, Sitko holds 79,224 shares of common stock directly, plus the 44,849 PSUs. He also reports direct holdings of preferred and depositary shares and additional indirect common and preferred holdings through a 401(k) plan, his spouse, and children.
Trigilio Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp Chief Financial Officer Jeffrey Trigilio received new equity awards that increase his direct ownership stake. On March 11, 2026, he was granted 138,462 Performance Stock Units, each representing a contingent right to one share of common stock, and 90,000 restricted stock units payable in common stock.
The 90,000 restricted stock units vest in four equal 25% installments on the first four anniversaries of January 12, 2026, as long as he continues serving the company. The performance stock units vest only if the common stock reaches a specified price per share and he remains in service through the applicable vesting dates.